Лучшие больницы для «Alpha-1-Antitrypsin Deficiency» в Бангалор, Индия
10 больниц по направлению «Трансплантация печени и гепатобилиарная хирургия» представлены в нашей сети в Индия, Бангалор, с аккредитацией NABH, JCI, NABL, ISO 9001.
На этой странице перечислены больницы направления «Трансплантация печени и гепатобилиарная хирургия» (включая Alpha-1-Antitrypsin Deficiency) в Бангалор, Индия, включая Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru и другие.
Спросите нас о «Alpha-1-Antitrypsin Deficiency» в Бангалор, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 10 аккредитованных больниц (Трансплантация печени и гепатобилиарная хирургия) в Бангалор, Индия
Рекомендуем🇮🇳 Narayana Health
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 1750 отзывов).
🇮🇳 Manipal Hospitals
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 1450 отзывов).
🇮🇳 Medicover Hospital, Bangalore
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 68 отзывов).
🇮🇳 Gleneagles Hospitals, Bengaluru
Больница занимает 4-е место в этом списке по указанному рейтингу (4.7/5, 142 отзывов).
🇮🇳 Manipal Hospital Malleshwaram (Northside)
Больница занимает 5-е место в этом списке по указанному рейтингу (4.6/5, 71 отзывов).
🇮🇳 Manipal Hospital, Old Airport Road
Больница занимает 6-е место в этом списке по указанному рейтингу (4.5/5, 87 отзывов).
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
Больница занимает 7-е место в этом списке по указанному рейтингу (4.5/5, 98 отзывов).
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.4/5, 74 отзывов).
🇮🇳 Apollo Hospital, Bannerghatta Road
Больница занимает 9-е место в этом списке по указанному рейтингу (4.2/5, 25 отзывов).
🇮🇳 Fortis Hospital, Bannerghatta Road
Больница занимает 10-е место в этом списке по указанному рейтингу (4.2/5, 58 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Бангалор, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «alpha-1-antitrypsin deficiency» в Бангалор, Индия?
Выбор подходящей больницы для «alpha-1-antitrypsin deficiency» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Трансплантация печени и гепатобилиарная хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Alpha-1-Antitrypsin Deficiency»
Alpha-1-Antitrypsin Deficiency (AATD) is a serious inherited metabolic disorder that leads to progressive emphysema and liver disease; AAT augmentation therapy (intravenous infusion of purified human alpha-1-antitrypsin) is the only disease-modifying treatment proven to slow lung function decline in Pi*ZZ and related phenotypes, with clinical studies demonstrating a statistically significant reduction in CT-measured lung density loss and annual FEV1 decline. International patients travelling to India and the UAE through GAF Healthcare benefit from access to JCI- and NABH-accredited pulmonology and hepatology centres staffed by subspecialty-trained AATD experts, at a fraction of Western costs and with seamless end-to-end medical concierge support. GAF Healthcare coordinates every aspect of the patient journey — from diagnostic confirmation and therapy initiation to long-term monitoring planning — across leading hospitals in Mumbai, Delhi, Chennai, Dubai, and Abu Dhabi. Hospital Stay: 1–2 days per infusion cycle (outpatient or short-stay); 5–10 days for initial diagnostic work-up and therapy induction if travelling internationally • Total Stay in Country (Fit-to-Fly): 1–2 weeks for initial evaluation, therapy initiation, and tolerance monitoring before international travel home; ongoing therapy requires return visits every 4–8 weeks or coordination with a home infusion provider • Success Rate: Augmentation therapy reduces annual CT lung density decline by approximately 34% compared to placebo (RAPID trial data); liver-directed therapies (RNA interference, gene therapy trials) show 80–95% target engagement in early-phase studies. Overall treatment response (stabilisation of lung function trajectory) is documented in 70–85% of compliant patients.
Clinical Overview
Alpha-1-Antitrypsin Deficiency (AATD) is an autosomal co-dominant genetic disorder caused by mutations in the SERPINA1 gene, most commonly the Pi*Z (Glu342Lys) allele. The resulting misfolded AAT protein is retained within hepatic endoplasmic reticulum, reducing circulating AAT to less than 11 µmol/L — far below the protective threshold of 35 µmol/L needed to neutralise neutrophil elastase in alveolar tissue. The unopposed elastase activity progressively destroys alveolar walls, producing panlobular emphysema with a characteristic basal predominance on high-resolution CT (HRCT). Concurrently, hepatic polymer accumulation triggers endoplasmic reticulum stress, chronic inflammation, and in susceptible patients, cirrhosis and hepatocellular carcinoma. The pulmonary phenotype typically manifests between the third and fifth decades of life as exertional dyspnoea, reduced exercise tolerance, and accelerated FEV1 decline (80–150 mL/year versus 30 mL/year in non-deficient smokers). Spirometry classically reveals an obstructive pattern (FEV1/FVC < 0.70) with air trapping (elevated RV/TLC) and reduced DLCO. HRCT quantitative densitometry — specifically the 15th percentile lung density (PD15) at full inspiration — is the most sensitive imaging biomarker for disease progression and is used in pivotal clinical trials as a primary endpoint. Liver involvement ranges from neonatal cholestasis and childhood hepatitis to adult-onset cirrhosis, detectable by liver stiffness measurement (FibroScan®) and serum biomarkers (ALT, GGT, bilirubin, INR). The internationally recognised standard of care for Pi*ZZ individuals with FEV1 15–65% predicted and documented lung density loss is weekly intravenous AAT augmentation therapy using FDA/EMA-approved plasma-derived concentrates — Prolastin-C (Grifols), Zemaira (CSL Behring), Glassia (Takeda), or Respreeza (CSL Behring, available in Europe). Beyond augmentation, management follows a multidisciplinary model integrating pulmonary rehabilitation, optimised COPD pharmacotherapy (LABA/LAMA/ICS combinations), vaccination, and for end-stage disease, lung volume reduction surgery or bilateral lung transplantation. Emerging liver-targeted therapies — including fazirsiran (ARO-AAT, an RNA interference agent) and NTLA-2002 (CRISPR-Cas9 base editing) — are in Phase 2/3 trials and available at select academic centres in India and the UAE under compassionate use or clinical trial frameworks.
Who is a Candidate?
• CONFIRMED PHENOTYPE: Pi*ZZ, Pi*ZNull, Pi*SZ, or other severe AATD genotypes confirmed by serum AAT level (< 11 µmol/L or < 57 mg/dL by nephelometry) AND SERPINA1 genotyping or isoelectric focusing (IEF) • PULMONARY ELIGIBILITY FOR AUGMENTATION: FEV1 15–65% predicted on spirometry; CT-documented emphysema (quantitative PD15 densitometry); non-smoker or smoking cessation confirmed ≥ 6 months; absence of IgA deficiency (risk of anaphylaxis to plasma products) • LIVER DISEASE EVALUATION: All AATD patients require baseline liver assessment — serum LFTs, FibroScan® (liver stiffness ≥ 7 kPa warrants enhanced surveillance), abdominal ultrasound, and AFP for HCC screening in cirrhotic patients • REQUIRED PRE-TREATMENT DIAGNOSTICS: Full pulmonary function tests (spirometry, body plethysmography, DLCO); HRCT thorax with quantitative densitometry; 6-minute walk test (6MWT) and SGRQ-C quality-of-life score; echocardiography (ECHO) to exclude pulmonary hypertension (RVSP > 40 mmHg modifies transplant candidacy); complete blood count, coagulation profile, serum protein electrophoresis; hepatitis B/C serology and HIV screening • LIVER TRANSPLANT CANDIDACY (selected patients): MELD score ≥ 15 in AATD-related cirrhosis; Child-Pugh Class B or C; absence of active extrahepatic malignancy; psychosocial evaluation clearance • LUNG TRANSPLANT CANDIDACY (end-stage): BODE index ≥ 7; FEV1 < 20% predicted; pO2 < 60 mmHg on room air; evaluation per ISHLT 2021 guidelines • CONTRAINDICATIONS TO AUGMENTATION THERAPY: Selective IgA deficiency with known anti-IgA antibodies; active hypersensitivity to human plasma-derived proteins; Pi*MS or Pi*MZ phenotype without serum AAT deficiency (augmentation not indicated) • RELATIVE CONTRAINDICATIONS: Active infection or sepsis (defer until resolved); severe decompensated heart failure (fluid load of IV infusion); pregnancy (insufficient safety data — risk-benefit discussion required)
Treatment Options & Approaches
STANDARD AAT AUGMENTATION THERAPY (INTRAVENOUS): Weekly IV infusion of purified, pasteurised, human plasma-derived alpha-1-antitrypsin concentrate at 60 mg/kg body weight, administered over 15–30 minutes in an outpatient or day-care setting. This is the only FDA-approved, EMA-approved disease-modifying therapy for AATD-related emphysema. The RAPID and RAPID-OLE trials (the only double-blind, placebo-controlled studies in AATD) demonstrated a 34% reduction in annual CT lung density loss (PD15 endpoint) and a significant benefit in FEV1 decline in the treatment arm over 4 years. Hospitals in India and the UAE offer all four internationally approved concentrates through verified cold-chain pharmaceutical procurement, with dose preparation handled by clinical pharmacists under aseptic conditions. OPTIMISED COPD PHARMACOTHERAPY (CONCURRENT): AATD-related emphysema is managed alongside standard GOLD-guideline COPD therapy: dual bronchodilation with LABA/LAMA combinations (indacaterol/glycopyrronium, tiotropium/olodaterol), triple therapy (fluticasone furoate/umeclidinium/vilanterol) for frequent exacerbators, and PDE4 inhibitor roflumilast for chronic bronchitis phenotype. Mucolytics, pulmonary rehabilitation (minimum 20 supervised sessions), and non-invasive ventilation (NIV/BiPAP) for hypercapnic respiratory failure are integrated into the treatment plan. LIVER-DIRECTED THERAPIES (INVESTIGATIONAL/COMPASSIONATE USE): For patients with significant hepatic polymer accumulation and liver fibrosis, emerging therapies include: (1) Fazirsiran (ARO-AAT) — subcutaneous RNAi agent targeting SERPINA1 hepatic mRNA, achieving 80–90% reduction in hepatic Z-AAT polymer in Phase 2 AROAAT2002 trial; available at select trial sites in India (AIIMS, CMC Vellore) and UAE (Cleveland Clinic Abu Dhabi); (2) NTLA-2002 — in vivo CRISPR base-editing therapy in Phase 1/2; (3) Carbamazepine — an autophagy enhancer that reduces hepatic Z-AAT accumulation, used off-label in paediatric AATD liver disease; (4) Small-molecule correctors (similar to CFTR corrector strategy for cystic fibrosis) in preclinical-to-Phase-1 development. SURGICAL OPTIONS: Bronchoscopic Lung Volume Reduction (BLVR): For patients with severe heterogeneous emphysema (FEV1 20–45% predicted, RV > 175%, absence of collateral ventilation on Chartis assessment), endobronchial valve (EBV) placement — using Zephyr valves (Pulmonx) — achieves lobar atelectasis and functional improvement in FEV1 (mean +14.6% in LIBERATE trial). Available at advanced bronchoscopy centres in India (Apollo Hospitals, Medanta, Fortis) and the UAE (Mediclinic City Hospital Dubai, Cleveland Clinic Abu Dhabi). Lung Transplantation: Bilateral sequential lung transplantation (BSLT) is the definitive treatment for end-stage AATD emphysema (FEV1 < 20% predicted, BODE ≥ 7). AATD is one of the top four indications for lung transplant worldwide. 5-year survival post-lung transplant in AATD is 50–60% (ISHLT registry), superior to idiopathic COPD. India's lung transplant programme (Apollo Chennai, Medanta Gurugram, Fortis Bangalore) has performed over 300 cases with outcomes comparable to international benchmarks. Post-transplant augmentation therapy is not required as the donor lungs produce normal AAT. Liver Transplantation: For AATD-related end-stage liver disease (MELD ≥ 15, Child-Pugh C), orthotopic liver transplantation is curative — the donor liver produces normal AAT, correcting both the hepatic and (partially) the pulmonary deficiency. Living donor liver transplantation (LDLT) is widely available in India, reducing wait times significantly versus deceased-donor-only programmes. PULMONARY REHABILITATION (STANDARD OF CARE): A minimum 8-week structured programme including aerobic training (treadmill, cycle ergometry at 60–80% peak work rate), inspiratory muscle training, and nutritional optimisation. Programmes at JCI-accredited centres in India and the UAE incorporate wearable monitoring (SpO2, heart rate) and telerehabilitation follow-up for international patients returning home.
Восстановление
PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel): • GAF Healthcare coordinates remote review of available medical records: serum AAT level, SERPINA1 genotype report, spirometry, HRCT chest, and liver function tests • Hospital specialist team confirms eligibility and designs a personalised treatment protocol • GAF Healthcare assists with e-Medical Visa application for India (typically approved within 3 business days) or facilitates UAE entry clearance • Patient receives a detailed Pre-Travel Medical Pack: list of required fasting tests, medication reconciliation instructions, and travel health advisory PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–3): • Day 1: Airport reception by GAF Healthcare's dedicated patient coordinator; transfer to accredited hospital or partner accommodation • Day 1 afternoon: Admission for comprehensive baseline assessment — spirometry with bronchodilator response, body plethysmography, DLCO, 6MWT, ECHO, HRCT with quantitative densitometry (PD15 measurement), FibroScan® liver stiffness, complete blood panel, IgA level, serum protein electrophoresis, SERPINA1 genotype confirmation if not previously performed • Day 2: Multidisciplinary team (MDT) review — pulmonologist, hepatologist, clinical geneticist, and clinical pharmacist — to confirm diagnosis, phenotype, treatment eligibility, and therapy selection • Day 3: MDT report presented to patient; written informed consent obtained; therapy schedule confirmed PHASE 3 — THERAPY INITIATION (Days 4–7): • Day 4: First IV AAT augmentation infusion administered under supervised conditions (15–30 min infusion, 1-hour post-infusion observation for hypersensitivity reactions — fever, urticaria, anaphylaxis risk < 0.1% per infusion) • Pre-medication protocol: paracetamol and antihistamine administered 30 minutes before infusion as per institutional protocol • Vital signs (BP, SpO2, HR, temperature) monitored continuously during infusion and for 60 minutes post-infusion • Day 5–6: Patient education sessions — infusion technique (for future home infusion if appropriate), exacerbation recognition, action plans, inhaler optimisation, pulmonary rehabilitation introduction • Day 7: Second infusion if tolerated; repeat safety bloods (LFTs, FBC); physician review and travel clearance assessment PHASE 4 — RECOVERY & FIT-TO-FLY ASSESSMENT (Days 8–14): • Patients who tolerate the first two infusions without adverse reactions are typically cleared for international travel by Day 10–14 • Flight fitness is confirmed by the treating pulmonologist: SpO2 ≥ 92% on room air at rest, no acute exacerbation, stable haemodynamics • Patients with baseline SpO2 < 92% require a formal hypoxia altitude simulation test (HAST) to determine in-flight oxygen requirements • GAF Healthcare provides a comprehensive Medical Summary Report and a referral letter to the patient's home physician outlining the ongoing infusion schedule (60 mg/kg IV weekly), monitoring parameters (spirometry every 6 months, HRCT annually, FibroScan® annually), and emergency contact protocols PHASE 5 — LONG-TERM ONGOING THERAPY: • Augmentation therapy is lifelong; GAF Healthcare coordinates with home-country infusion centres or assists with periodic return visits to India or UAE for annual monitoring • Annual follow-up visit (1 week duration) recommended: repeat quantitative CT densitometry, spirometry, DLCO, 6MWT, liver assessment, and MDT review • Telemedicine follow-up consultations available through GAF Healthcare's partner network at 3-month intervals • Patients listed for lung or liver transplant undergo additional evaluation phases per ISHLT/ILTS guidelines
Возможные риски
AAT augmentation therapy has an established safety profile across three decades of clinical use, but patients and clinicians must consider the following specific risks and limitations: Infusion-Related Reactions: Occurring in approximately 0.02% of infusions, reactions range from mild (fever, chills, urticaria, myalgia) to severe anaphylaxis. Risk is highest in patients with undetected IgA deficiency; mandatory pre-screening eliminates most severe cases. All infusion centres at GAF Healthcare partner hospitals are equipped with anaphylaxis resuscitation kits and trained nursing staff. Blood-Borne Pathogen Transmission: Although modern plasma-derived AAT concentrates undergo rigorous viral inactivation (solvent/detergent treatment, nanofiltration, pasteurisation), a theoretical residual risk of non-enveloped virus transmission exists. All products used are FDA- and EMA-licensed with full lot traceability. Therapeutic Limitations: Augmentation therapy slows but does not halt or reverse existing emphysema. Patients with FEV1 < 15% or > 65% predicted do not meet evidence-based criteria for augmentation and should be counselled on alternative strategies. The therapy does not address the hepatic Z-AAT polymer accumulation — liver disease may progress independently. Surgical Risks (BLVR): Endobronchial valve placement carries risks of pneumothorax (risk 10–14% in first 72 hours post-procedure, highest in patients with collateral ventilation misassessed pre-procedure), valve migration (2–5%), mucus plugging causing lobar infection, and COPD exacerbation requiring prolonged hospitalisation. Lung Transplantation Risks: Primary graft dysfunction (PGD Grade 3, 10–20%), acute cellular rejection (30–40% within first year), chronic lung allograft dysfunction (CLAD/BOS, 50% at 5 years), and opportunistic infections (CMV pneumonitis, aspergillosis) are the major morbidity contributors. Immunosuppression is lifelong and requires vigilant monitoring. Liver Transplantation Risks: Vascular complications (hepatic artery thrombosis < 3%), biliary strictures (10–15%), acute rejection (20–30%), and graft-versus-host disease (rare in LDLT) are recognised complications. MELD score-correlated 90-day post-transplant mortality ranges from 2–8% at high-volume Indian centres. Long-Term Monitoring Obligation: Given the lifelong nature of augmentation therapy and the progressive hepatic and pulmonary disease trajectory, patients must commit to structured annual monitoring — CT densitometry, spirometry, FibroScan®, and HCC surveillance in cirrhotic patients. Non-compliance significantly diminishes therapeutic benefit.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated non-medical support infrastructure designed to eliminate barriers to international treatment access for AATD patients: e-MEDICAL VISA (INDIA): GAF Healthcare's visa facilitation team prepares and submits the e-Medical Visa application on the patient's behalf, typically securing approval within 72 hours. The e-Medical Visa permits multiple entries over 1 year with stays up to 60 days — ideal for patients requiring return infusion visits or transplant evaluation. Attendant visas (up to 2 family members) are processed simultaneously. UAE ENTRY (DUBAI / ABU DHABI): Over 50 nationalities enjoy visa-on-arrival or visa-free access to the UAE. For nationalities requiring advance visas, GAF Healthcare coordinates UAE medical visa applications directly with the DHA (Dubai Health Authority) or DOH (Department of Health Abu Dhabi). Medical treatment letters from partner hospitals expedite the process to 3–5 business days. AIRPORT TRANSFERS & GROUND LOGISTICS: Private, air-conditioned ambulance or premium vehicle transfers are arranged for all airport-to-hospital and hospital-to-hotel journeys. Wheelchair assistance, oxygen support during transfer (for hypoxic patients), and porter services are pre-arranged. DEDICATED PATIENT COORDINATORS & TRANSLATORS: Each patient is assigned a named GAF Healthcare coordinator fluent in the patient's native language (Arabic, Russian, Swahili, French, Uzbek, Bengali, and other major languages supported). Medical interpreters accompany patients to all consultations, procedure consents, and discharge briefings to ensure informed decision-making without language barriers. ACCOMMODATION FOR PATIENTS & ATTENDANTS: GAF Healthcare has negotiated preferential rates at medical-grade serviced apartments and partner hotels within 5–15 minutes of all network hospitals in Mumbai, Delhi, Chennai, Gurugram, Dubai, and Abu Dhabi. Attendant accommodation (single or twin configurations) is arranged for the full duration of the stay, including extended stays during transplant recovery. TELEMEDICINE CONTINUITY: Following return home, all patients have access to GAF Healthcare's telemedicine platform for virtual follow-up consultations with their treating specialist, prescription relay, and ongoing care coordination with home-country physicians. FINANCIAL TRANSPARENCY: GAF Healthcare provides a written cost estimate before travel — inclusive of all medical fees, hospital charges, and pharmacy costs — with no hidden billing. Direct hospital billing and insurance-liaison services are available for eligible patients.
Частые вопросы о процедуре «Alpha-1-Antitrypsin Deficiency»
What is the cost of Alpha-1-Antitrypsin Deficiency Treatment (AAT Augmentation Therapy) in India versus the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after starting AAT Augmentation Therapy?
What is the success rate of AAT Augmentation Therapy and related AATD treatments?
Как GAF Healthcare помогает выбрать лучшую больницу для «alpha-1-antitrypsin deficiency» в Бангалор, Индия
Найдите лучшие больницы для «alpha-1-antitrypsin deficiency» в Бангалор, Индия
На этой странице представлено 10 больниц в Бангалор, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Alpha-1-Antitrypsin Deficiency» в Бангалор, Индия
Сколько больниц направления «Трансплантация печени и гепатобилиарная хирургия» представлено в Бангалор, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Бангалор, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Alpha-1-Antitrypsin Deficiency» в Бангалор, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.